



04-18-03

RECEIVED

APR 24 2003

427.057

TECH. CENTER 1400/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
CHABRIERE DE LASSAUNIERE et al
Serial No.: 10/089,993
Filed: April 4, 2002
For: DERIVATIVES...MEDICAMENTS

Group: 1615

600 Third Avenue
New York, N.Y. 10036
April 17, 2003


INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:


Applicants are submitting herewith a copy of European patent application No. 0,513,387 which is pertinent to the above application. The present application is directed to thiadiazoles and the enclosed reference is directed to piperazinyl compounds. The same is being filed to comply with the requirements of Rule 56.

Respectfully submitted,
Muserlian, Lucas and Mercanti


Charles A. Muserlian, 19,683
Attorney for Applicants
Tel. # (212) 661-8000

CAM:ds
Enclosures

EV 34197181/43
APR 17 2003
Date of Deposit
I hereby certify that this paper or its copy is associated with the United States Patent Application No. 10/089,993, filed April 4, 2002, and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.
April 17, 2003
Chabriere



INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

DocId: 34461800

427 057

Application Number

10/089,993

Applicant CHABRIERE DE LASSAUNIERE et al

Filing Date 4/4/02

Group An Unit
1615

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO
0513387	11/91	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.